MAIA Biotechnology (MAIA) grants CSO 400,000 stock options at $1.39

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported that Chief Scientific Officer Sergei Gryaznov received a grant of stock options covering 400,000 shares of common stock. These options have an exercise price of $1.39 per share and expire on May 29, 2036.

The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting monthly over the following 36 months.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gryaznov Sergei

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	400,000	$0.00	--

Holdings After Transaction: Stock Options — 400,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 400,000 options Exercise price: $1.39 per share Expiration date: May 29, 2036 +3 more

6 metrics

Options granted 400,000 options Stock options covering 400,000 underlying common shares granted to CSO

Exercise price $1.39 per share Exercise price for the granted stock options

Expiration date May 29, 2036 Options expire on May 29, 2036

Vesting cliff 25% after 1 year 25% of options vest on first anniversary of grant

Remaining vesting period 36 months monthly Remaining 75% vest ratably monthly over 36 months

Shares following transaction 400,000 derivative securities Total stock options held following this grant

Key Terms

Stock Options, 2021 Equity Incentive Plan, vesting schedule, underlying security

4 terms

Stock Options financial

"The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."

vesting schedule financial

"representing the right to buy shares of common stock, vest on a 4-year vesting schedule..."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

underlying security financial

"underlying_security_title: "Common Stock", underlying_security_shares: "400000.0000""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gryaznov Sergei

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.39	05/29/2026		A		400,000		(1)	05/29/2036	Common Stock	400,000	$0	400,000	D

Explanation of Responses:

1. The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	/s/ Sergei M. Gryaznov	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA (MAIA) report on this Form 4?

MAIA reported that Chief Scientific Officer Sergei Gryaznov received a grant of stock options for 400,000 shares. These derivative securities allow him to buy common stock at a fixed exercise price of $1.39 per share until May 29, 2036, subject to vesting.

What is the exercise price and expiration date of Sergei Gryaznov’s MAIA options?

The granted stock options have an exercise price of $1.39 per share and expire on May 29, 2036. This means he can purchase MAIA common shares at $1.39 any time before expiration, once the options have vested according to the plan’s schedule.

How do the 400,000 MAIA stock options granted to the CSO vest over time?

The 400,000 stock options vest on a four-year schedule. Twenty-five percent vest on the first anniversary of the May 29, 2026 grant, and the remaining options vest ratably each month over the next 36 months, encouraging long-term retention and alignment with shareholders.

Under which plan were Sergei Gryaznov’s MAIA options granted and what do they represent?

The options were granted under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan and represent the right to buy common shares. They are compensation-related awards, not open-market purchases, and their value depends on MAIA’s stock price exceeding the $1.39 exercise level in the future.

Does this MAIA Form 4 show a stock purchase or sale by the CSO?

The Form 4 shows a grant of stock options, not a market purchase or sale of common shares. It records a compensation award giving the CSO the right to acquire 400,000 shares at $1.39 per share if and when the options vest and are exercised.